— Know what they know.
Not Investment Advice
Also trades as: 0UNL.L (LSE) · $vol 0M

NKTR NASDAQ

Nektar Therapeutics
1W: -3.2% 1M: -37.1% 3M: -46.3% YTD: -12.6% 1Y: -36.8% 3Y: +390.6% 5Y: -84.8%
$37.97
+0.52 (+1.39%)
 
Weekly Expected Move ±13.7%
$27 $32 $37 $42 $47
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 30 · $1.1B mcap · 29M float · 3.86% daily turnover · Short 50% of daily vol
Credit Risk of going bust: higher than 66% of companies Debt: 11.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.56 (down 99%), Nektar Therapeutics would be worth roughly what it owes.
Total debt $135.9M against a stock market value of $1.09B.
Distance to default 3.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $51.4M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -3.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Supply Chain Overview

4 relationships
4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2024-03-04
Earliest Filing
2024-12-02
Latest Filing
acquirer: 2 partner: 1 investor: 1

Counterparties (Filed by NKTR)

4 relationships

Companies named in NKTR's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
Ampersand Capital Partners — acquirer Affiliate of Ampersand Management LLC that acquired Nektar's manufacturing facility and assets. 2024-12-02 View
Ampersand Capital Partners — acquirer Purchaser of Nektar's manufacturing facility and assets for $90 million 2024-11-04 View
Ampersand Management LLC — partner Parent entity of the Purchaser affiliate 2024-11-04 View
TCG Crossover Fund II, L.P. — investor Purchased 25,000,000 pre-funded warrants for $30.0 million in a private placement. 2024-03-04 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-10-01 Regulation FD; Exhibits View
2026-09-25 Other Events View
2026-09-08 Regulation FD; Exhibits View
2026-08-13 Earnings Release; Exhibits View
2026-06-05 Shareholder Vote View
2026-05-08 Material Agreement; Officer/Director Change; Exhibits Agreement View
2026-05-07 Earnings Release; Exhibits View
2026-04-23 Material Agreement; Other Events; Exhibits Agreement View
2026-04-20 Regulation FD; Other Events; Exhibits View
2026-04-20 Regulation FD View
2026-03-12 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2026-02-13 Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits Agreement View
2026-02-10 Regulation FD Disclosure View
2026-02-10 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2026-01-27 Regulation FD Disclosure; Financial Statements and Exhibits View
2025-12-16 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2025-11-21 Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits View
2025-11-10 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
2025-11-06 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-09-18 Regulation FD Disclosure; Other Events; Financial Statements and Exhibits View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms